Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
No Thumbnail Available
Identifiers
Date
2018-10-01
Authors
Arce-Lara, C.
Arriola, E.
Brunsvig, P.
Carcereny, E.
Domine, M.
Dragnev, K.
Felip, E.
Garcia Campelo, R.
Krebs, M.
Paz-Ares, L.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Axl, pembrolizumab, combination